Exodus Point Capital Management, LP Cti Biopharma Corp Transaction History

Exodus Point Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$4.2 - $6.01 $2.7 Million - $3.87 Million	643,530 Added 208.39%	952,343 $4 Million
Q4 2022 Feb 13, 2023	BUY	$4.45 - $6.17 $1.37 Million - $1.91 Million	308,813 New	308,813 $1.86 Million
Q2 2022 Aug 19, 2022	SELL	$3.55 - $6.27 $287,251 - $507,343	-80,916 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$1.9 - $5.23 $153,740 - $423,190	80,916 New	80,916 $378,000
Q2 2021 Aug 16, 2021	SELL	$2.16 - $2.62 $409,354 - $496,531	-189,516 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$2.68 - $3.8 $124,086 - $175,943	-46,301 Reduced 19.63%	189,516 $551,000
Q4 2020 Feb 16, 2021	BUY	$2.48 - $3.8 $584,826 - $896,104	235,817 New	235,817 $759,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.